Study study type PathologyT1T0Patientssample sizesROB Results

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus regorafenib
atezolizumab plus cometinib
IMblaze-370 (AC ; all population), 2019
  NCT02788279
RCTmCRC - 2nd line (L2)atezolizumab plus cometinibregorafenibpatients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.183 / 90some concern
inconclusive
  • inconclusive 0 % increase in deaths (OS) (PE)